Targeted therapies for rare gynaecological cancers
Authors:
- Chupong IttiwutCIChupong Ittiwut
- Apiwat MutiranguraAMApiwat Mutirangura
- John J KavanaghJKJohn J Kavanagh
- 1 July 2010
- journal article
- review article
- Published by Elsevier in The Lancet Oncology
- Vol. 11 (7) , 685-693
Abstract
No abstract availableKeywords
This publication has 68 references indexed in Scilit:
- Clinical management of uterine sarcomasThe Lancet Oncology, 2009
- Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumorsGynecologic Oncology, 2009
- The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: A case reportGynecologic Oncology, 2008
- Management of granulosa cell tumour of the ovaryCurrent Opinion in Oncology, 2008
- Glucose metabolism and angiogenesis in granulosa cell tumors of the ovary: Activation of Akt, expression of M2PK, TKTL1 and VEGFEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2008
- Expression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumorsGynecologic Oncology, 2008
- Anastrozole therapy in recurrent ovarian adult granulosa cell tumors: A report of 2 casesGynecologic Oncology, 2006
- Hormonal treatment of a recurrent granulosa cell tumor of the ovary: case report and review of the literatureGynecologic Oncology, 2005
- Transrepression of Estrogen Receptor β Signaling by Nuclear Factor-κB in Ovarian Granulosa CellsMolecular Endocrinology, 2004
- Combined inhibition of VEGF‐ and PDGF‐signaling enforces tumor vessel regression by interfering with pericyte‐mediated endothelial cell survival mechanismsThe FASEB Journal, 2003